Table 1. Baseline characteristics by randomization treatment arm in the study population overall.
| Overall | ||
|---|---|---|
|
| ||
| Placebo (n=118) | Spirono (n=121) | |
| Age (years) | 70.7 ± 8.4 | 69.7 ± 9.5 |
| Female | 53%) | 51% |
| White | 89% | 84% |
| Enrollment Strata: Prior Hospitalization | 64% | 59% |
| Co-morbidities | ||
| Hypertension | 97% | 89% |
| Myocardial Infarction | 27% | 31% |
| Coronary Revascularization | 30% | 31% |
| Stroke | 7% | 12% |
| Atrial Fibrillation | 44% | 42% |
| Diabetes | 34% | 36% |
| Obesity | 53% | 58% |
| NYHA Functional Class | ||
| 1 | 6% | 5% |
| 2 | 59% | 61% |
| 3 | 36% | 32% |
| 4 | 0% | 2% |
| Physical Characteristics | ||
| BMI (kg/m2) | 32.0 ± 7.4 | 32.8 ± 7.3 |
| Heart rate (bpm) | 68 ± 12 | 65 ± 11 |
| Systolic blood pressure (mmHg) | 126 ± 14 | 127 ± 14 |
| Diastolic blood pressure (mmHg) | 73 ± 11 | 74 ± 10 |
| Laboratory Values | ||
| eGFR (mL/min per 1.73 m2) | 67.5 ± 18.1 | 67.9 ± 19.0 |
| Creatinine (mg/dL) | 1.07 ± 0.29 | 1.10 ± 0.32 |
| Hematocrit (%) | 38.6 ± 4.8 | 39.4 ± 4.6 |
No significant differences for baseline comparisons with the exception of hypertension (p=0.03).; BMI=body mass index; eGFR= estimated glomerular filtration rate